www.dailypolitical.com ·
shuttle pharmaceuticals nasdaqshph releases earnings results
Topic context
This topic has been covered 327419 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedShuttle Pharmaceuticals is a micro-cap biotech company. The earnings release shows continued losses, but no specific product pipeline, revenue, or cost mechanism is discussed. The stock movement is likely driven by low liquidity and speculative trading rather than a fundamental commercial shift. No concrete commercial mechanism (e.g., drug approval, partnership, supply chain event) is identified.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Shuttle Pharmaceuticals (NASDAQ:SHPH) reported quarterly earnings loss of $0.43 per share on May 15, 2026.
- Stock rose 4.0% to $0.67, with volume 454,298 shares (avg 2,360,916).
- Market cap $3.72 million, 52-week range $0.50-$6.19.
- Consensus rating 'Sell', Weiss Ratings upgraded from 'sell (e)' to 'sell (e+)'.
- Institutional investors increased stakes; Connective Capital Management leads with $357,000 investment.
